相关实验视频
用罗西格利塔和美特福林低剂量联合治疗以预防2型糖尿病 (CANOE试验):一项双盲随机对照研究
Bernard Zinman1, Stewart B Harris, Jan Neuman
1Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada. zinman@lunenfeld.ca
Lancet (London, England)
|July 8, 2010
概括
低剂量罗西格利塔和美特福林显著降低了葡萄糖耐受性受损的患者2型糖尿病的发展. 这种组合疗法在预防糖尿病方面被证明是有效的,副作用是可以控制的.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 临床试验 临床试验
背景情况:
- 2型糖尿病流行需要有效的预防策略.
- 在CANOE试验中,评估了用于预防糖尿病的低剂量组合疗法.
研究的目的:
- 为了研究低剂量罗西格利塔和美特福林联合治疗在预防2型糖尿病方面的疗效.
- 评估这种治疗方法在葡萄糖耐受性受损的患者中的安全性和有效性.
主要方法:
- 这是一项双盲随机对照试验,对207名葡萄糖耐受性受损的患者进行了随机对照试验.
- 参与者每天接受两次罗西格利塔 (2毫克) 和甲胺 (500毫克) 或安慰剂,平均时间为3.9年.
- 主要结局:通过口服葡萄糖耐受性测试或禁食血葡萄糖的糖尿病发病时间.
主要成果:
- 与安慰剂 (39%) 相比,积极治疗组的参与者患糖尿病的人数显著减少 (14%).
- 在糖尿病发病率方面,相对风险降低66%,绝对风险降低26%.
- 80%的治疗组回归到正常的葡萄糖耐受性,而安慰剂组的回归率为53%. 在治疗组观察到腹增加.
结论:
- 低剂量罗西格利塔和美特福林的联合治疗在预防葡萄糖耐受性受损的患者的2型糖尿病方面非常有效.
- 组合疗法在重大不良事件方面表现出有利的安全性.
- 这种方法为糖尿病预防提供了一个可行的策略.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...